Clinical Trials
30 trialsValproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
National Cancer Institute, Naples
SWITCH
University of California, San Diego
ATARI-PDAC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
SELECTIO-UC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
The First Affiliated Hospital with Nanjing Medical University
AGNOSTOS
Fondazione del Piemonte per l'Oncologia
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
Mayo Clinic
ATRiUM
Cambridge University Hospitals NHS Foundation Trust
GEMFOX
Assistance Publique - Hôpitaux de Paris
STAR_PAC
Barts & The London NHS Trust
PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
University of California, San Francisco
Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors
University of Cincinnati
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
University of Pittsburgh
Immunochemoradiotherapy in Patients With Pancreatic Cancer
Providence Health & Services
PanHIPEC
University Hospital Tuebingen
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
HAI Abraxane With Gemcitabine and Bevacizumab
M.D. Anderson Cancer Center
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
Samsung Medical Center
Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer
Haukeland University Hospital
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
Rutgers, The State University of New Jersey
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
Rigshospitalet, Denmark
Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)
Johannes Gutenberg University Mainz
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors
Washington University School of Medicine
NEOPACHI-001
Erasme University Hospital
Gemox as First and Second Line Therapy in Unknown Primary Cancer
M.D. Anderson Cancer Center
Cetuximab + Gemox in Biliary Tract Cancer
Association of Research on the Biology of Liver Tumors
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
University of Michigan Rogel Cancer Center
Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary
Gustave Roussy, Cancer Campus, Grand Paris